A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
This study is for adults living with a heart condition called non-obstructive hypertrophic cardiomyopathy, where the heart muscle is thickened but doesn't block blood flow. Participants will receive either a new experimental tablet called Aficamten or a placebo (a dummy pill with no active medicine). The main goal is to find out if Aficamten helps people feel better in their daily lives and improves their ability to exercise, compared to the placebo. Researchers will also be looking at other important health markers and overall heart health over time. This is a "Phase 3" study, which means it's a large, final stage trial before a new medicine might be considered for wider use.
At a glance
What is this study about?
Imagine your heart muscle is thickened, making it harder for your heart to pump blood effectively, but without a blockage. This is called non-obstructive hypertrophic cardiomyopathy. It can make you feel tired, short of breath, and limit what you can do. This study is testing a new medication called Aficamten as a potential treatment for this condition. We want to see if it can help people manage their symptoms better and improve their quality of life.
This important study is designed to compare Aficamten against a placebo, which is a tablet that looks exactly like Aficamten but contains no active medicine. This comparison is vital because it helps researchers understand if any improvements seen are truly due to the medicine or simply because someone is taking a pill (the 'placebo effect'). Neither you nor your doctor will know whether you are taking Aficamten or the placebo; this is called a 'double-blind' study and ensures the results are as fair and unbiased as possible.
The main things we'll be looking at are how your symptoms change over time (how you feel in daily activities) and your ability to exercise. We'll also be tracking other important health markers, like changes in your heart function and overall heart health, to get a complete picture of how Aficamten might help. If successful, this study could lead to a new treatment option for people with non-obstructive hypertrophic cardiomyopathy.
Key takeaways
- This study evaluates a new drug, Aficamten, for a specific heart condition.
- It aims to improve symptoms and exercise ability in people with non-obstructive hypertrophic cardiomyopathy.
- Participants will receive either Aficamten or a placebo (dummy pill).
- It's a 'double-blind' study, meaning you won't know which you are taking.
- The study lasts about 36 weeks and involves regular clinic visits.
- Participation is voluntary, and you can withdraw at any time.
Who may be eligible?
This study is looking for adults who have been diagnosed with symptomatic non-obstructive hypertrophic cardiomyopathy. This means you must have symptoms from your heart condition and your heart muscle thickening should not be causing a blockage to blood flow.
To be considered, you must be at least 18 years old. People of all genders are welcome to participate. There will be other specific health requirements and tests to make sure the study is right and safe for you, and to ensure the results are clear.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with hypertrophic cardiomyopathy (HCM)?
- Are you experiencing symptoms from your HCM (e.g., breathlessness, tiredness)?
- Has your doctor confirmed that your HCM is 'non-obstructive' (meaning there's no blockage to blood flow)?
- Are you able to attend regular clinic appointments for about 9 months?
What does participation involve?
If you decide to take part, you would be involved in this study for about 36 weeks, which is roughly 8 to 9 months. During this time, you would have regular visits to the clinic for check-ups and tests. These visits are important to monitor your health, how you're feeling, and any changes in your heart condition.
You would take either the study medication (Aficamten) or a placebo tablet daily. You, and your study doctor, will not know which one you are taking. You will have various assessments, including questionnaires about your symptoms and daily activities, and tests to measure your exercise ability. There will also be blood tests and heart scans (like an ECG) to check your heart health and how well the treatment is working. After the 36 weeks of treatment, there will likely be some follow-up appointments to see how you are doing.
Potential risks and benefits
Locations (11)
- —UnverifiedPoland
- —UnverifiedSpain
- —UnverifiedItaly
- —UnverifiedHungary
- —UnverifiedFrance
- —UnverifiedGermany
- —UnverifiedNetherlands
- —UnverifiedDenmark
- —UnverifiedPortugal
- —UnverifiedGreece
- —UnverifiedIceland
Common questions
What is 'non-obstructive hypertrophic cardiomyopathy'?
It's a heart condition where your heart muscle is thicker than it should be, making it harder to pump blood, but there isn't a blockage to the blood flow leaving your heart.
What is a 'placebo'?
A placebo is a dummy pill that looks exactly like the study drug but contains no active medicine. It helps researchers fairly compare the new drug's effects.
Will I know if I'm taking the real drug or the placebo?
No, this is a 'double-blind' study, meaning neither you nor your study doctor will know whether you are taking Aficamten or the placebo. This helps keep the study fair.
How long will I be involved in the study?
If you join, you would be involved for about 36 weeks, which is approximately 8 to 9 months, including regular clinic visits and taking the study medication.
Can I leave the study if I change my mind?
Yes, absolutely. You can withdraw from the study at any time, for any reason, and it will not affect your ongoing medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.